RNA interference (RNAi) gene therapy against HIV-1 by stable expression of antiviral short hairpin RNAs (shRNAs) can potently inhibit viral replication in T cells. Recently, a mouse model with a human immune system (HIS) was developed that can be productively infected with HIV-1.
In this in vivo model, in which Rag-2 À/À g c À/À mice are engrafted with human CD34 + CD38
À hematopoietic precursor cells, we evaluated an anti-HIV RNAi gene therapy. Human hematopoietic stem cells were transduced with a lentiviral vector expressing an shRNA against the HIV-1 nef gene (shNef) or the control vector. We observed normal development of the different cell subsets of the immune system. However, although initial transduction efficiencies were similar for both vectors, a reduced percentage of transduced human immune cells was observed for the shNef vector after establishment of the HIS in vivo. Multiple anti-retroviral drugs are available that inhibit HIV-1 replication. Currently, patients are treated with a combination of drugs known as highly active antiretroviral therapy (HAART), which can effectively control the infection. [1] [2] [3] However, adherence to the drug regimen is an important prerequisite for the success of HAART, which can be further complicated by severe side effects. Suboptimal levels of medication, resulting from irregular intake, can result in the selection of drugresistant virus variants and treatment failure. 1 Thus, there is a need for alternative therapeutic strategies to treat HIV-1 infection. Gene therapy approaches, in which HIV-1-susceptible cells are rendered resistant to the virus in a single treatment, have the potential to significantly improve the quality of life of HIV-1-infected individuals. 4 In such a gene therapy, the antiviral products are exclusively produced in the genetically modified cells, and toxic side effects linked with the systemic application of drugs should thus be avoided.
The discovery of RNA interference (RNAi) 5 provides a potent sequence-specific gene regulatory mechanism that can be added to the gene therapy arsenal against HIV. 4, 6 Efficient and durable inhibition of HIV-1 replication can be achieved when an RNAi inducer directed against the virus is stably expressed as a short hairpin RNA (shRNA) in T-cell lines. [7] [8] [9] [10] Several target cells for HIV infection are found in the immune system, in particular CD4 + T lymphocytes, monocytes, macrophages and dendritic cells. These cellular subsets derive from a self-maintained pool of human hematopoietic stem cells, which differentiate to give rise to progenitors of both the myeloid and lymphoid lineages. It is therefore attractive to consider hematopoietic stem cell transduction with lentiviral vectors as a gene therapy approach for shRNA delivery. 4, 6 Engraftment of autologous transduced hematopoietic stem cells will eventually result in the steady production of HIV-1-resistant immune cells that may lead to (partial) reconstitution of the immune system.
We have previously characterized the effects of the potent antiviral shNef that targets a sequence present in all viral transcripts. 8, 11 Using a retroviral vector-transduced T-cell line, we observed that shNef potently inhibited HIV-1 replication in vitro. However, the in vivo safety and efficacy of such an approach still remains elusive. The SIV/macaque model, 12 although mainly used for vaccine studies, may be considered for a preclinical safety test. However, this model has severe limitations because HIV-based lentiviral vector transduction is restricted by TRIM5a in macaque cells. 13 In addition, as RNAi is a sequence-specific mechanism, anti-HIV shRNAs should either be changed to anti-SIV shRNAs or HIV-1 target sequences have to be incorporated into the SIV genome. These limitations of the expensive SIV/macaque model do not apply to humanized mouse models. 14 We and others have recently established BALB/c Rag-2 À/À g c À/À newborn mice as a new xenograft model for the in vivo study of development and function of the human immune system (HIS). 15, 16 In this HIS (BALB-Rag/g) mouse model, all major human myeloid and lymphoid cellular compartments develop and mature, [17] [18] [19] giving access to in vivo and ex vivo experimentation on human T cells. 20 It has already been demonstrated that HIS (BALB-Rag/g) mice support both R5-and X4-tropic HIV-1 infection, including rectal and vaginal transmission routes, which result in typical pathogenesis of CD4 + depletion and viremia, similar to infected patients. [21] [22] [23] [24] [25] [26] Here, we tested the shNef inhibitor in the HIS (BALB-Rag/g) mouse model as a relevant in vivo model for an eventual anti-HIV gene therapy.
We constructed a third-generation self-inactivating lentiviral vector 27, 28 JS1-shNef, which contains an expression cassette for an shRNA against the HIV-1 nef gene ( Figure 1 ). The SupT1 T-cell line, which is fully susceptible to HIV-1 replication, was transduced with the lentiviral vectors JS1 and JS1-shNef at a low multiplicity of infection, and transduced cells were selected with live sorting for green fluorescent protein (GFP) expression. Subsequently, the SupT1 cell lines were infected either with wild-type HIV-1 (HIV-1 wt ) or an HIV-1 variant that is resistant to shNef due to two point mutations within the target sequence (HIV-1 R3 ; Figure 1 ). 8, 11 The JS1-shNef SupT1 cells infected with the wild-type virus were viable and no syncytia were observed, whereas massive virusinduced syncytia and cell death was observed 10 days post infection in control JS1 and untransduced SupT1 cells. This observation was confirmed by measuring CAp24 levels in the supernatant as a read-out for viral replication. Wild-type viral production in JS1-shNef cells was 3 logs reduced compared with control and JS1 cells ( + T cells demonstrate that shNef selectively inhibits wild-type HIV-1 replication, confirming the sequencespecificity that is typical for RNAi. Moreover, it also demonstrates that the expression of shNef did not intrinsically affect the capacity of transduced cells to support HIV-1 replication, as the shNef-resistant virus replicated equally well in JS1-shNef, JS1 and control cells.
As transduction with the JS1-shNef vector did not exhibit apparent negative effects on SupT1 and T cells ex vivo, we next studied whether shNef expression in human hematopoietic stem cells would have an impact on hematopoiesis in vivo. For this purpose, human fetal liver CD34 + CD38 À hematopoietic progenitors were isolated by fluorescence-activated cell sorting and transduced with the JS1-shNef or JS1 vector. Both vectors exhibited equivalent transduction efficiencies, as assessed 3-4 days later by GFP expression (Figure 3a) . The hematopoietic progenitors, comprising a mixture of transduced and nontransduced cells, were inoculated into newborn BALB/c Rag-2 À/À g c À/À recipient mice (13 to 14 animals per group in two independent experiments). After 7 weeks, the two groups of animals were analyzed for the presence of human hematopoiesisderived CD45 + cells in the blood (Figure 3b ). The frequency of human cells was similar between the two groups (JS1: 31.2 ± 6.9% vs JS1-shNef: 37.0 ± 7.5%; n ¼ 13 to 14 mice per group). However, when we analyzed the percentage of transduced (GFP + ) human cells, a significant difference was observed between the JS1 and JS1-shNef groups. For the JS1 group we observed a ) and 10% fetal calf serum (1 Â 10 5 in 0.2 ml) were infected with 0.05 ng CA-p24. Virus spread was monitored by measuring CA-p24 production with ELISA.
Evaluating the efficacy of RNAi against HIV-1 O ter Brake et al topoietic precursor cells, when compared with the control JS1. We observed the same effect with another shRNA directed against the HIV-1 integrase sequences (unpublished results). Similar trends can also be observed in two recent publications, although not specifically addressed by the authors. A safety and efficacy study was conducted in the SCID-hu mouse with a lentiviral vector containing three anti-HIV genes, expressing a CCR5 ribozyme, TAR decoy and an anti-HIV shRNA, 32 and in macaques with an SIV-based lentiviral vector expressing an shRNA against CCR5. 33 This reduction may be a reason for concern from a safety point of view, especially when considering combinatorial RNAi as a gene therapy approach for HIV-1. 9, 34, 35 Further experimentation is needed to determine the actual safety implications and the underlying mechanism, which may ; n ¼ 14 for the control JS1 group, n ¼ 13 for the shNef group). The CD4/CD8 T-cell ratio is also given (mean±s.d.). There were no statistical differences between the two groups within GFP À or GFP + cells. The HIS mice were generated as previously described. 15, 16 Human fetal liver was obtained from elective abortions, and use of this tissue was approved by the Medical Ethical Committee of the AMC-UvA and was contingent on informed consent. Purified CD34 + CD38
À progenitors were cultured overnight in IMDM (Invitrogen, Carlsbad, CA, USA) supplemented with Yssel's medium, 5% normal human serum, 20 ng ml À1 human stem cell factor (PeproTech, Rocky Hill, NJ, USA), 20 ng ml À1 human thrombopoietin (PeproTech) and 20 ng ml À1 human interleukin-7 (PeproTech). The next day, cells were incubated for 6-8 h with control JS1 or shNef vector supernatant in fibronectin-coated plates (30 mg ml
À1
; Takara Biomedicals, Otsu, Shiga, Japan) after which the cells (5-10 Â 10 5 ) were inoculated via intrahepatic injection into newborn (o1 week old) H-2 d Rag-2 À/À g c À/À mice 31 that had received sublethal (3.5 Gy) totalbody irradiation with an X-ray Rö ntgen source. Mononuclear cells from blood were isolated by density gradient centrifugation 7-8 weeks post-transplantation. Cell suspensions were labeled with anti-human mAb targeting the following cell surface markers: CD1a (T6-RD1; Coulter-Immunotech), CD3 (SK7), CD4 (SK3), CD8 (SK1), CD19 (HIB19) and CD45 (2D1; BD Bioscience, Franklin Lakes, NJ, USA) and analyzed using a LSR-II (BD Bioscience) cytometer interfaced to FACS-Diva software system. Data were subjected to two-tail unpaired Student's t-test analysis; *Po0.05.
Evaluating the efficacy of RNAi against HIV-1 O ter Brake et al include an impact on the endogenous microRNA pathway, an off-target effect specific for shNef, a general shRNA effect, a reduced vector integration, silencing of GFP expression, a reduced hematopoietic stem cell viability or engraftment efficiency. Nevertheless, the in vivo development and maturation of the immune system were not affected, consistent with the results in the other animal models. 32, 33 Thus, despite an apparent reduction in the percentage of JS1-shNef-reduced cells, development of the immune system is normal, which indicates that the approach can be considered to be safe. Importantly, we show for the first time that an antiviral RNAi-based gene therapy on blood stem cells results in in vivo development of mature human T cells in which HIV-1 replication is inhibited in a sequence-specific manner. Thus, our results provide an important proof of principle for the clinical development of RNAi-based gene therapies against HIV-1. 
CD1a
À CD4 + CD8 À ) and the presence or absence of GFP expression. Cells from three to six HIS (BALB-Rag/g) mice were pooled and subsequently stimulated for 2 days with PHA (4 mg ml À1 ) in RPMI culture medium supplemented with IL-2 (100 U ml À1 ) and 10% fetal calf serum. The human CD4 + T cells sorted from the HIS (BALB-Rag/g) mice (6 Â 10 4 in 0.2 ml) were infected with virus supernatant (0.2 ng CA-p24) and virus spread was monitored by measuring CA-p24 production with ELISA. The HIV-1 wt inhibition experiment was repeated four times; a representative experiment is shown. GFP, green fluorescent protein.
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